Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells

Japanese Journal of Cancer Research

Volumn 91, Issue 2, 2000, Pages 213-222

  Tsai, Chun Ming ^a,b   Chang, Kuo Ting ^a   Li, Lan ^c   Perng, Reury Perng ^b   Yang, Li Ying ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cisplatin resistance; Epidermal growth factor receptor; HER 2 neu; Non small cell lung cancer; Nucleotide excision repair

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEOTIDE;

ARTICLE; CANCER CELL CULTURE; CHEMOSENSITIVITY; CORRELATION FUNCTION; DNA REPAIR; DRUG RESPONSE; EXCISION REPAIR; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE NEU; PRIORITY JOURNAL;

EID: 0034105946     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00934.x     Document Type: Article

References (62)

1. Parsons, J. T. and Parsons, S. J. Protein-tyrosine kinases, oncogenes, and cancer. In "Important Advances in Oncology," ed. V. T. DeVita, Jr., S. Hellman and S. A. Rosenberg, pp. 3-18 (1993). J. B. Lippincott Co., Philadelphia.
2. Hynes, N. E. and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198, 165-184 (1994).
3. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S. and Sugimachi, K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res., 50, 7077-7080 (1990).
4. ERBB2 expression and the gene amplification. Cancer Res., 50, 8002-8009 (1990).
5. Schneider, P. M., Hung, M. C., Chiocca, S. M., Manning, J., Zhao, X., Fang, K. and Roth, J. A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res., 49, 4968-4971 (1989).
6. Arteaga, C. L. Epidermal growth factor receptors and erbB-2 in human lung cancer. In "Lung Cancer: Principles and Practice," ed. H. J. Pass, J. B. Mitchell, D. H. Johnson and A. T. Turrisi, pp. 99-106 (1996). Lippincott-Raven Publ., Philadelphia.
7. Maurizi, M., Scambia, G., Benedetti-Panici, P., Ferrandina, G., Almadori, G., Paludetti, G., De Vincenzo, R., Distefano, M., Brinchi, D., Cadoni, G. and Mancuso, S. EGF receptor expression in primary laryngeal cancer: correlation with clinicopathological features and prognostic significance. Int. J. Cancer, 52, 862-866 (1992).
8. Neal, D. E., Marsh, C. and Bennett, M. K. Epidermal growth factor receptors in human bladder cancer: comparison of invasive and superficial tumors. Lancet, i, 366-368 (1985).
9. Sainsbury, J. R. C., Farndon, J. R., Needham, G. K., Malcolm, A. J. and Harris, A. L. Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, i, 1398-1402 (1987).
10. Scambia, G., Benedetti-Panici, P., Ferrandina, G., Battaglia, F., Distefano, M., D'andrea, G., De Vincenzo, R., Maneschi, F., Ranelletti, F. O. and Mancuso, S. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int. J. Cancer, 56, 26-30 (1994).
11. Scambia, G., Benedetti-Panici, P., Distefano, M., Salerno, G., Romanini, M. E., Fagotti, A. and Mancuso, S. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer, 72, 361-366 (1995).
12. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A. and Press, M. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244, 707-712 (1989).
13. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50, 5184-5191 (1990).
14. Tateishi, M., Ishida, T., Mitsudomi, T., Kaneko, S. and Sugimachi, K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer, 27, 1372-1375 (1991).
15. Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L. and McGuire, W. L. J. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10, 599-605 (1992).
16. Tsai, C. M., Chang, K. T., Perng, R. P., Mitsudomi, T., Chen, M. H., Kadoyama, C. and Gazdar, A. F. Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst., 85, 897-901 (1993).
17. Tsai, C. M., Chang, K. T., Wu, L. H., Chen, J. Y., Gazdar, A. F., Mitsudomi, T., Chen, M. H. and Perng, R. P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res., 56, 206-209 (1996).
18. neu in the HER-2/neu transfected human lung cancer cells. J. Natl. Cancer Inst., 87, 682-684 (1995).
19. Yu, D., Liu, B., Tan, M., Li, J., Wang, S. S. and Hung, M. C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene, 13, 1359-1365 (1996).
20. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M. and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24, 85-95 (1992).
21. Alaoui-Jamali, M. A., Paterson, J., Moustafa, A. I. and Yen, L. The role of ErbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem. Cell Biol., 75, 315-325 (1997).
22. neu expressing non-small cell lung cancer cells. Cancer Res., 56, 1068-1074 (1996).
23. Zhang, L. and Hung, M. C. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene, 12, 571-576 (1996).
24. Hancock, M. C., Langton, B. C., Chan, T., Toy, P., Monahan, J. J., Mischak, R. P. and Shawver, L. K. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res., 51, 4575-4580 (1991).
25. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegrum, M. D., Howell, S. B. and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9, 1829-1838 (1994).
26. Arteaga, C. L., Winnier, A. R., Poirier, M. C., Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D. and Stewart, S. J. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54, 3758-3765 (1994).
27. Yen, L., Nie, Z. R., You, X. L., Richard, S., Langton-Webster, B. C. and Alaoui-Jamali, M. A. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway. Oncogene, 14, 1827-1835 (1997).
28. neu expressing human non-small cell lung cancer cell lines. J. Natl. Cancer Inst., 86, 1018-1020 (1994).
29. neu. Cancer Res., 56, 794-801 (1996).
30. Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J. and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene, 15, 537-547 (1997).
31. Christen, R. D., Hem, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom, L. and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest., 86, 1632-1640 (1990).
32. Kroning, R., Jones, J. A., Hom, D. K., Chuang, C. C., Sanga, R., Los, G., Howell, S. B. and Christen, R. D. Enhancement of drug sensitivity of human malignancies by epidermal growth factor. Br. J. Cancer, 72, 615-619 (1995).
33. Dixit, M., Yang, J. L., Poirier, M. C., Price, J. O., Andrews, P. A. and Arteaga, C. L. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J. Natl. Cancer Inst., 89, 365-373 (1997).
34. Dickstein, B. M., Wosikowski, K. and Bates, S. E. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol. Cell. Endocrinol., 110, 205-211 (1995).
35. Fan, Z., Baselga, J., Masui, H. and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloraplatinum on well established A431 cell xenografts. Cancer Res., 53, 4637-4642 (1993).
36. Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., Jr. and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85, 1327-1333 (1993).
37. Aghajanian, C., Zhuo, Y., Ho, T. Y., Brown, C., Fan, Z., Baselga, J., Mendelsohn, J. and Spriggs, D. R. Anti-epidermal growth factor receptor monoclonal antibody treatment of A431 cells decreases cisplatin/DNA adduct repair in association with NF-KB induction [abstract]. Proc. Am. Assoc. Cancer Res., 36, 427 (1995).
38. Coussens, L., Yang-Feng, T. L., Liao, Y. C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T., Schlessinger, J., Francke, U., Levinson, A. and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132-1139 (1985).
39. Wen, D., Suggs, S. V., Karunagaran, D. and Liu, N. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol. Cell. Biol., 14, 1909-1919 (1994).
40. Peles, E. and Yarden, Y. Neu and its ligands: from an oncogene to neural factors. BioEssays, 15, 815-824 (1994).
41. neu: a potential model for receptor interactions. EMBO J., 7, 995-1001 (1988).
42. erbB2. J. Biol. Chem., 268, 2924-2931 (1993).
43. Goldman, R., Ben Levy, R., Peles, E. and Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 29, 11024-11028 (1990).
44. Spivak-Kroizman, T., Rotin, D., Pinchasi, D., Ullrich, A., Schlessinger, J. and Lax, I. Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses. J. Biol. Chem., 267, 8056-8063 (1992).
45. Kokai, Y., Meyers, J. N., Wada, T., Brown, V. I., LeVea, C. M., Davis, J. G., Dobashi, K. and Greene, M. I. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell, 58, 287-292 (1989).
46. Zamble, D. and Lippard, S. J. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci., 20, 435-439 (1995).
47. Huang, J. C., Zamble, D. B., Reardon, J. T., Lippard, S. J. and Sancar, A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl. Acad. Sci. USA, 91, 10394-10398 (1994).
48. Hansson, J. and Wood, R. D. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum (II). Nucleic Acids Res., 20, 8073-8091 (1989).
49. Li, L., Liu, X., Glassman, A. B., Keating, M. J., Stros, M., Plunkett, W. and Yang, L. Y. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res., 57, 1487-1494 (1997).
50. Manley, J. L., Fire, A., Samuels, M. and Sharp, P. A. In vitro transcription: whole cell extract. Methods Enzymol., 101, 568-582 (1983).
51. Shivji, M. K. K., Podust, V. N., Hubscher, U. and Wood, R. D. Nucleotide excision repair DNA synthesis by DNA polymerase ∈ in the presence of PCNA, RFC, and RPA. Biochemistry, 34, 5011-5017 (1995).
52. Zeng-Rong, X., Paterson, J., Alpert, L., Tsao, M. S., Viallet, J. and Alaoui-Jamali, M. A. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res., 55, 4760-4764 (1995).
53. Tsai, C. M., Chang, K. T., Perng, R. P. and Chen, J. Y. Epidermal growth factor modulates chemosensitivity of non-small cell lung cancer cells through its effect on cell proliferation. Proc. Am. Assoc. Cancer Res., 38, 195 (1997).
54. Weidner, U., Peter, S., Strohmeyer, T., Hussnatter, R., Ackermann, R. and Sies, H. Inverse relationship of epidermal growth factor receptor and HER-2/neu gene expression in human renal cell carcinoma. Cancer Res., 50, 4504-4509 (1990).
55. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78, 539-542 (1994).
56. Liebermann, D. A., Hoffman, B. and Steinman, R. A. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene, 11, 199-210 (1995).
57. Vaux, D. L. and Strasser, A. The molecular biology of apoptosis. Proc. Natl. Acad. Sci. USA, 93, 2239-2244 (1996).
58. cdc2 kinases. Mol. Cell, 2, 581-591 (1998).
59. Volm, M., Kastel, M., Mattern, J. and Efferth, T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer, 71, 3981-3987 (1993).
60. Yang, J. M., Sullivan, G. F. and Hait, W. N. Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem. Pharmacol., 53, 1597-1604 (1997).
61. Allen, G. C., Lubas, S., Wax, M. K. and Devore, R. F., III Epidermal growth factor regulates topoisomerase II activity and drug sensitivity in human KB cells. Otolaryngol. Head Neck Surg., 114, 785-792 (1996).
62. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Fiermann, W., Wolter, J., Baselga, J. and Norton, L. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc. Am. Soc. Clin. Oncol., 17, 98a (1998).